Log in to search using one of your social media accounts:

 

New mutations related to hereditary neuroendocrine tumours
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The presence of a germline mutation in the GOT2 gene found in a patient with metastasis gives rise to increased activity of the encoder enzyme. Furthermore, the authors describe extraordinarily rare mutations in two patients: one in the SDHC gene and another in the IDH1. Finally, by way of an extension study focused on more than 60 patients with these neuroendocrine tumours, a new susceptibility gene, IDH3B, associated with the development of paragangliomas was identified. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2017 Category: International Medicine & Public Health Source Type: news

Wait - and - Scan Strategy Feasible for Head, Neck Paraganglioma
Large group of tumors found not to grow, although they did elicit complications (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 17, 2017 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Radiology, Surgery, Journal, Source Type: news

Treatment of Head and Neck Paragangliomas Treatment of Head and Neck Paragangliomas
Is first-line treatment for carotid body tumors the same as that for jugular and vagal paragangliomas?Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Preoperative Management for Phaeochromocytoma/Paraganglioma Preoperative Management for Phaeochromocytoma/Paraganglioma
Find out what the available evidence tells us about the preoperative management of patients with phaeochromocytomas and paragangliomas.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New study links'mastermind' gene to rare cancer-causing tumor
Scientists have discovered a new " mastermind fusion gene " may be associated with a rare cancer-causing tumor -- pheochromocytomas ( " pheo " ) and paragangliomas -- according to a study. This breakthrough discovery could lead to more precise treatment as well as a better understanding of cancer itself. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 13, 2017 Category: Science Source Type: news

In-depth gene search reveals new mutations, drug targets in rare adrenal tumors
(University of Pennsylvania School of Medicine) Casting one of the largest genomic nets to date for the rare tumors of the autonomic nervous system known as pheochromocytoma and paraganglioma (PCC/PGL) captured several new mutations driving the disease that could serve as potential drug targets, researchers from Penn Medicine and other institutions reported this week in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2017 Category: Global & Universal Source Type: news

Perioperative Care of PhaeochromocytomaPerioperative Care of Phaeochromocytoma
This article reviews the essentials of perioperative care and monitoring in patients with pheochromocytomas and paragangliomas. BJA Education (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2016 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Adrenoceptor Blockade for Hormonally Functional Pheo/PGLAdrenoceptor Blockade for Hormonally Functional Pheo/PGL
A new study examines whether patients with hormonally functional pheochromocytomas and paragangliomas (pheo/PGLs) are receiving the appropriate pharmacological treatment. Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Published in Hormone and Metabolic Research, a study found that paediatric patients with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times more likely to also carry a diagnosis of ADHD. Clinical Endocrinology News (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 20, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Pediatric News)
Source: Pediatric News - May 19, 2016 Category: Journals (General) Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - May 19, 2016 Category: Endocrinology Source Type: news

TERT promoter mutations in adrenal tumours
The telomerase reverse transcriptase gene (TERT) is essential for telomere stabilization and cell immortalization. A role for TERT promoter mutations C228T and C250T has been demonstrated in aggressive human cancer. The underlying mechanisms of telomerase activation is not known in adrenal tumors. Liu and colleagues assessed C228T and C250T TERT mutations, finding that TERT promoter mutation C228T is a recurrent event associated with adrenocortical carcinoma, but rarely occurs in paraganglioma or pheochromocytoma. The involvement of the TERT gene in adrenocortical carcinoma is a new finding. Read the full article at Liu e...
Source: Society for Endocrinology - June 26, 2014 Category: Endocrinology Source Type: news

Endocrine Society First to Address Rare Adrenal-Tumor CareEndocrine Society First to Address Rare Adrenal-Tumor Care
New clinical practice guidelines are the first ever to address management of patients with pheochromocytoma and paraganglioma, rare adrenal tumors that can be fatal if not diagnosed. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 5, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 27, 2014 Category: Endocrinology Source Type: news

Exome sequencing in phaeochromocytoma/paraganglioma
In this study, McInerney-Leo et al. have assessed whether whole exome sequencing (WES), using an off-the-shelf exome capture platform rather than designing individual targeted assays, is a sensitive, time- efficient and cost-effective way to offer genetic testing in a population of individuals with established diagnosis of PCC/PGL. They also evaluated the target capture of the currently available exome capture platforms for exons of the known PCC/PGL genes. They demonstrate that WES accurately diagnosed all mutations in all 11 patients with PCC/PGL in whom mutations had been detected previously by Sanger sequencing. Furth...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

Long-term prognosis in pediatric pheochromocytoma
A third of patients with paraganglial tumors, pheochromocytoma, and paraganglioma, carry germline mutations in one of the susceptibility genes, RET, VHL, NF1, SDHAF2, SDHA, SDHB, SDHC, SDHD, TMEM127, and MAX. Despite increasing importance, data for long-term prognosis are scarce in pediatric presentations. Using the European–American–Pheochromocytoma–Paraganglioma Registry as a platform, Bausch and colleagues report the first and only population-based study of longterm outcomes in pediatric pheochromocytoma. Read the full article at Bausch et al. (2014) Endocrine-Related Cancer 21; 17&nda...
Source: Society for Endocrinology - January 24, 2014 Category: Endocrinology Source Type: news

Gene susceptibility testing in phaeochromocytoma and paraganglioma
Recent studies have suggested that around one-third of individuals with phaeochromocytoma or paraganglioma have an inherited genetic predisposition, prompting some calls for genetic testing in all patients with phaeochromocytoma or paraganglioma. Such a strategy is expensive, and variation between populations is large. Jafri and colleagues analysed data from a 10-year period in the West Midlands PPGL/HNPGL database, finding that clinical risk factors (positive family history, multiple tumours, earlier age at onset) could be used to target genetic testing in a cost-effective manner, though universal testing would be require...
Source: Society for Endocrinology - June 12, 2013 Category: Endocrinology Source Type: news

Level of tumor protein indicates chances cancer will spread
Contact: Robert Bock or Marianne Glass Miller 301-496-5133 Level of tumor protein indicates chances cancer will spread NIH researchers seek to develop test to guide treatment Researchers at the National Institutes of Health and the University of Hong Kong have discovered that high levels of a particular protein in cancer cells are a reliable indicator that a cancer will spread. By measuring the protein’s genetic material in tumors that had been surgically removed from patients, along with measuring the genetic material from surrounding tissue, the researchers could predict at least 90 percent of the time whether a c...
Source: Kidney Cancer Association - February 2, 2011 Category: Urology & Nephrology Source Type: news